Shares Outstanding Shares Outstanding n/a Close	27.12M
Shares Change (YoY) Shares Change (YoY) n/a Close	0.7%
Shares Change (QoQ) Shares Change (QoQ) n/a Close	0.12%
Owned by Institutions (%) Owned by Institutions (%) n/a Close	98.49%
Shares Floating Shares Floating n/a Close	24.83M
Failed to Deliver (FTD) Shares Failed to Deliver (FTD) Shares n/a Close	19
FTD / Avg. Volume FTD / Avg. Volume n/a Close	n/a

Short Selling Information

The latest short interest is 5.5M, so 20.3% of the outstanding shares have been sold short.

Short Interest Short Interest n/a Close	5.5M
Short % of Shares Out Short % of Shares Out n/a Close	20.3%
Short % of Float Short % of Float n/a Close	31.4%
Short Ratio (days to cover) Short Ratio (days to cover) n/a Close	12.84

Valuation Ratios

The PE ratio is -5.66 and the forward PE ratio is -5.05. Arcturus Therapeutics's PEG ratio is -0.03.

PE Ratio PE Ratio n/a Close	-5.66
Forward PE Forward PE n/a Close	-5.05
PS Ratio PS Ratio n/a Close	3.31
Forward PS Forward PS n/a Close	0.5
PB Ratio PB Ratio n/a Close	1.9
P/FCF Ratio P/FCF Ratio n/a Close	-7.59
PEG Ratio PEG Ratio n/a Close	-0.03

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Arcturus Therapeutics.

EV / Sales EV / Sales n/a Close	n/a
EV / EBITDA EV / EBITDA n/a Close	n/a
EV / EBIT EV / EBIT n/a Close	n/a
EV / FCF EV / FCF n/a Close	n/a

Financial Position

The company has a current ratio of 4.67, with a Debt / Equity ratio of 0.12.

Current Ratio Current Ratio n/a Close	4.67
Quick Ratio Quick Ratio n/a Close	4.67
Debt / Equity Debt / Equity n/a Close	0.12
Debt / EBITDA Debt / EBITDA n/a Close	-0.37
Debt / FCF Debt / FCF n/a Close	-0.47
Interest Coverage Interest Coverage n/a Close	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity Return on Equity n/a Close	n/a
Return on Assets Return on Assets n/a Close	n/a
Return on Invested Capital Return on Invested Capital n/a Close	n/a
Revenue Per Employee Revenue Per Employee n/a Close	$795,339.08
Profits Per Employee Profits Per Employee n/a Close	$-465,178.16
Employee Count Employee Count n/a Close	174
Asset Turnover Asset Turnover n/a Close	0.4
Inventory Turnover Inventory Turnover n/a Close	n/a

Taxes

Income Tax Income Tax n/a Close	-4K
Effective Tax Rate Effective Tax Rate n/a Close	0%

Stock Price Statistics

The stock price has increased by -41.1% in the last 52 weeks. The beta is 2.29, so Arcturus Therapeutics's price volatility has been higher than the market average.

Beta Beta n/a Close	2.29
52-Week Price Change 52-Week Price Change n/a Close	-41.1%
50-Day Moving Average 50-Day Moving Average n/a Close	12.23
200-Day Moving Average 200-Day Moving Average n/a Close	16
Relative Strength Index (RSI) Relative Strength Index (RSI) n/a Close	65.79
Average Volume (20 Days) Average Volume (20 Days) n/a Close	450,846

Income Statement

In the last 12 months, Arcturus Therapeutics had revenue of 138.39M and earned -80.94M in profits. Earnings per share was -3.

Revenue Revenue n/a Close	138.39M
Gross Profit Gross Profit n/a Close	134.84M
Operating Income Operating Income n/a Close	-95.67M
Net Income Net Income n/a Close	-80.94M
EBITDA EBITDA n/a Close	-77.4M
EBIT EBIT n/a Close	-80.94M
Earnings Per Share (EPS) Earnings Per Share (EPS) n/a Close	-3

Full Income Statement

Balance Sheet

The company has 237.03M in cash and 28.55M in debt, giving a net cash position of 208.48M.

Cash & Cash Equivalents Cash & Cash Equivalents n/a Close	237.03M
Total Debt Total Debt n/a Close	28.55M
Net Cash Net Cash n/a Close	208.48M
Retained Earnings Retained Earnings n/a Close	-448.81M
Total Assets Total Assets n/a Close	331.79M
Working Capital Working Capital n/a Close	229.38M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -59.75M and capital expenditures -648K, giving a free cash flow of -60.4M.

Operating Cash Flow Operating Cash Flow n/a Close	-59.75M
Capital Expenditures Capital Expenditures n/a Close	-648K
Free Cash Flow Free Cash Flow n/a Close	-60.4M
FCF Per Share FCF Per Share n/a Close	-2.24

Full Cash Flow Statement

Margins

Gross margin is 97.44%, with operating and profit margins of -69.13% and -58.49%.

Gross Margin Gross Margin n/a Close	97.44%
Operating Margin Operating Margin n/a Close	-69.13%
Pretax Margin Pretax Margin n/a Close	-58.49%
Profit Margin Profit Margin n/a Close	-58.49%
EBITDA Margin EBITDA Margin n/a Close	-55.93%
EBIT Margin EBIT Margin n/a Close	-69.13%
FCF Margin FCF Margin n/a Close	-43.64%

Dividends & Yields

ARCT does not appear to pay any dividends at this time.

Dividend Per Share Dividend Per Share n/a Close	n/a
Dividend Yield Dividend Yield n/a Close	n/a
Dividend Growth (YoY) Dividend Growth (YoY) n/a Close	n/a
Payout Ratio Payout Ratio n/a Close	n/a
Earnings Yield Earnings Yield n/a Close	n/a
FCF Yield FCF Yield n/a Close	n/a

Dividend Details

Analyst Forecast

The average price target for ARCT is $52.5, which is 264.6% higher than the current price. The consensus rating is "Buy".

Price Target Price Target n/a Close	$52.5
Price Target Difference Price Target Difference n/a Close	264.6%
Analyst Consensus Analyst Consensus n/a Close	Buy
Analyst Count Analyst Count n/a Close	7

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value Lynch Fair Value n/a Close	n/a
Lynch Upside Lynch Upside n/a Close	n/a
Graham Number Graham Number n/a Close	n/a
Graham Upside Graham Upside n/a Close	n/a

Stock Splits

The last stock split was on Nov 16, 2017. It was a backward split with a ratio of 1:7.

Last Split Date Last Split Date n/a Close	Nov 16, 2017
Split Type Split Type n/a Close	backward
Split Ratio Split Ratio n/a Close	1:7

Scores

Altman Z-Score Altman Z-Score n/a Close	0.61
Piotroski F-Score Piotroski F-Score n/a Close	2